MolPharm xPharm- The Comprehensive Pharmacology Reference

Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
 QUICK SEARCH:   [advanced]


     


This Article
Right arrow Full Text (PDF)
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Longabaugh, J. P.
Right arrow Articles by Stiles, G. L.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Longabaugh, J. P.
Right arrow Articles by Stiles, G. L.

Modification of the rat adipocyte A1 adenosine receptor-adenylate cyclase system during chronic exposure to an A1 adenosine receptor agonist: alterations in the quantity of GS alpha and Gi alpha are not associated with changes in their mRNAs

JP Longabaugh, J Didsbury, A Spiegel and GL Stiles

Department of Biochemistry, Duke University Medical Center, Durham, North Carolina 27710.

The A1-adenosine receptor (A1AR) adenylate cyclase system in rat adipocytes undergoes heterologous desensitization following chronic in vivo exposure to an A1AR agonist (+)-N6-(R-phenylisopropyl)adenosine [J. Biol. Chem. 262:841-847 (1987)]. This desensitization involves an absolute increase in adenylate cyclase activity and a refractoriness to receptor ligands that are inhibitory to adenylate cyclase. In this study, receptor changes were characterized using an A1AR antagonist radioligand, [3H]8-[4-[[[[(2-aminoethyl)amino]carbonyl]methyl] oxy]phenyl]-1,3-dipropyl xanthine. Saturation binding studies demonstrated a 47% decrease in total A1AR density without a change in KD. Agonist competition studies revealed a decreased percentage of receptors, from 55% to 35%, in the high affinity state following desensitization. An increase in GS alpha of 49% was found by Western blotting using specific GS alpha antibodies. Further, an antibody that recognizes Gi alpha 1 adn Gi alpha 2 was used to quantitate these subtypes of Gi alpha and both were decreased by 59% following desensitization. However, when an antibody that recognizes Gi alpha 3 was used, no change in Gi alpha 3 was found, demonstrating, in this case, differential regulation of Gi alpha subtypes. The mechanisms responsible for changes in GS alpha and Gi alpha were studied by measuring the levels of their mRNAs from normal and desensitized adipocytes. Using either labeled cDNAs (Gi alpha 2, Gi alpha 3) or oligonucleotides (GS alpha, Gi alpha 1), Northern analysis demonstrated that mRNAs for GS alpha and all three isoforms of Gi alpha are present in adipocytes but that there are no changes in the levels of any of these transcripts following desensitization. These data suggest that desensitization of the A1AR-adenylate cyclase system involves a down- regulation of A1ARs and an additional loss of A1AR agonist high affinity sites. Further, an increase in GS alpha, a decrease in Gi alpha 1 and Gi alpha 2, and no change in Gi alpha 3 were found. The regulation of GS alpha and the subtypes of Gi alpha in this system does not occur by altering the levels of their respective transcripts.

Volume 36, Issue 5, pp. 681-688, 11/01/1989
Copyright © 1989 by American Society for Pharmacology and Experimental Therapeutics




This article has been cited by other articles:


Home page
J. Pharmacol. Exp. Ther.Home page
S. Jajoo, D. Mukherjea, S. Pingle, Y. Sekino, and V. Ramkumar
Induction of Adenosine A1 Receptor Expression by Pertussis Toxin via an Adenosine 5'-Diphosphate Ribosylation-Independent Pathway
J. Pharmacol. Exp. Ther., April 1, 2006; 317(1): 1 - 10.
[Abstract] [Full Text] [PDF]


Home page
J. Neurosci.Home page
D. Blum, D. Gall, M.-C. Galas, P. d'Alcantara, K. Bantubungi, and S. N. Schiffmann
The Adenosine A1 Receptor Agonist Adenosine Amine Congener Exerts a Neuroprotective Effect against the Development of Striatal Lesions and Motor Impairments in the 3-Nitropropionic Acid Model of Neurotoxicity
J. Neurosci., October 15, 2002; 22(20): 9122 - 9133.
[Abstract] [Full Text] [PDF]


Home page
Pharmacol. Rev.Home page
B. B. Fredholm, A. P. IJzerman, K. A. Jacobson, K.-N. Klotz, and J. Linden
International Union of Pharmacology. XXV. Nomenclature and Classification of Adenosine Receptors
Pharmacol. Rev., December 1, 2001; 53(4): 527 - 552.
[Abstract] [Full Text] [PDF]


Home page
Mol. Pharmacol.Home page
S. Ginés, F. Ciruela, J. Burgueño, V. Casadó, Enric. I. Canela, J. Mallol, C. Lluís, and R. Franco
Involvement of Caveolin in Ligand-Induced Recruitment and Internalization of A1 Adenosine Receptor and Adenosine Deaminase in an Epithelial Cell Line
Mol. Pharmacol., April 16, 2001; 59(5): 1314 - 1323.
[Abstract] [Full Text]


Home page
J. Appl. Physiol.Home page
G. B. Carey
Cellular adaptations in fat tissue of exercise-trained miniature swine: role of excess energy intake
J Appl Physiol, March 1, 2000; 88(3): 881 - 887.
[Abstract] [Full Text] [PDF]


Home page
HypertensionHome page
T. Hussain, R. Abdul-Wahab, D. K. Kotak, and M. F. Lokhandwala
Bromocriptine Regulates Angiotensin II Response on Sodium Pump in Proximal Tubules
Hypertension, December 1, 1998; 32(6): 1054 - 1059.
[Abstract] [Full Text] [PDF]


Home page
Pharmacol. Rev.Home page
V. Ralevic and G. Burnstock
Receptors for Purines and Pyrimidines
Pharmacol. Rev., September 1, 1998; 50(3): 413 - 492.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
C. A. Saura, J. Mallol, E. I. Canela, C. Lluis, and R. Franco
Adenosine Deaminase and A1 Adenosine Receptors Internalize Together following Agonist-induced Receptor Desensitization
J. Biol. Chem., July 10, 1998; 273(28): 17610 - 17617.
[Abstract] [Full Text] [PDF]


Home page
Biol. Reprod.Home page
J.-L. Lécrivain, J. Cohen-Tannoudji, M.-T. Robin, N. Coudouel, C. Legrand, and J.-P. Maltier
Molecular Mechanisms of Adenylyl Cyclase Desensitization in Pregnant Rat Myometrium following In Vivo Administration of the ss-Adrenergic Agonist, Isoproterenol
Biol Reprod, July 1, 1998; 59(1): 45 - 52.
[Abstract] [Full Text]


Home page
Am. J. Physiol. Endocrinol. Metab.Home page
B. Xu, D. A. Berkich, G. H. Crist, and K. F. LaNoue
A1 adenosine receptor antagonism improves glucose tolerance in Zucker rats
Am J Physiol Endocrinol Metab, February 1, 1998; 274(2): E271 - E279.
[Abstract] [Full Text] [PDF]


Home page
Mol. Pharmacol.Home page
F. Ciruela, C. Saura, E. I. Canela, J. Mallol, C. Lluís, and R. Franco
Ligand-Induced Phosphorylation, Clustering, and Desensitization of A1 Adenosine Receptors
Mol. Pharmacol., November 1, 1997; 52(5): 788 - 797.
[Abstract] [Full Text]


Home page
Mol. Pharmacol.Home page
Z. Nie, Y. Mei, and V. Ramkumar
Short Term Desensitization of the A1 Adenosine Receptors in DDT1MF-2 Cells
Mol. Pharmacol., September 1, 1997; 52(3): 456 - 464.
[Abstract] [Full Text]


Home page
StrokeHome page
S. M. Shreeve, M. A. Shatos, and E. Thorin
{alpha}-Thrombin Upregulates G{alpha}i3 in Human Vascular Endothelial Cells
Stroke, December 1, 1996; 27(12): 2211 - 2215.
[Abstract] [Full Text]


Home page
CirculationHome page
T. Eschenhagen, U. Mende, M. Diederich, B. Hertle, C. Memmesheimer, A. Pohl, W. Schmitz, H. Scholz, M. Steinfath, M. Bohm, et al.
Chronic Treatment With Carbachol Sensitizes the Myocardium to cAMP-Induced Arrhythmia
Circulation, February 15, 1996; 93(4): 763 - 771.
[Abstract] [Full Text]


Home page
J. Biol. Chem.Home page
T. M. Palmer, T. W. Gettys, and G. L. Stiles
Differential Interaction with and Regulation of Multiple G-proteins by the Rat A[IMAGE] Adenosine Receptor
J. Biol. Chem., July 14, 1995; 270(28): 16895 - 16902.
[Abstract] [Full Text] [PDF]




Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
 Molecular Interventions Drug Metabolism and Disposition

Copyright © 1989 by the American Society for Pharmacology and Experimental Therapeutics